At REVIVEBIO, our core strength lies in world-class scientific research and a deeply experienced professional team. Backed by decades of academic and clinical research, our R&D team specializes in Next-Generation Probiotics (NGPs) and bioactive polysaccharides from traditional Chinese medicine. We are committed to developing precision microbiome-based interventions targeting a wide range of critical health conditions, including obesity and metabolic syndrome, chronic obstructive pulmonary disease (COPD), Helicobacter pylori infection, and autism spectrum disorder (ASD).
To date, our team has published over 200 peer-reviewed papers in top-tier international journals across areas such as gut microbiota, immune modulation, and inflammation. Our work is featured in leading scientific publications, including Nature Medicine, Nature Communications, Nature Reviews Gastroenterology & Hepatology, Trends in Pharmacological Sciences, GUT, and Protein & Cell, affirming REVIVEBIO’s global impact and scientific credibility in microbial medicine.
REVIVEBIO’s strategy is to transform robust scientific research into biotechnology innovations for therapeutic, health and beauty applications. We focus on the anti-aging potential of NGPs, with targeted benefits in immunomodulation, sarcopenia prevention, osteoporosis, skin and gut aging, neuroinflammation, chronic kidney disease, cognitive resilience, colorectal cancer prevention, metabolic health, liver function, and circadian rhythm regulation.
Our proprietary NGP strain, Parabacteroides goldsteinii, has demonstrated potent anti-inflammatory effects validated by leading global research institutions, including Massachusetts Institute of Technology, Harvard University, Université de Montréal, and Xi’an Jiaotong University. Its mechanisms and health benefits have been featured in Science (2022), GUT (2023), and Cell Host & Microbe (2024), underscoring the innovation behind our technology platform.
In addition, we have proactively advanced global regulatory and intellectual property strategies based on our preclinical research results. These efforts include third-party GRAS (Generally Recognized As Safe), FDA regulatory submissions, and PCT international patent deployment. As our R&D enters the critical translational phase toward clinical trials and commercialization, REVIVEBIO will collaborate with leading global brands in the health and skincare industries to accelerate the market implementation of our innovations. By translating scientific advances into market-ready solutions, we aim to leverage our technological leadership and broaden our influence throughout Asia and the global biotech landscape.
